Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KCNN4 | O15554 | 7/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016877 | 0.85 | MAPT (0.63) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL28380853 | 0.83 | MAPT (0.48) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL2781433 | 0.76 | MAPT (0.68) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL368343 | 0.76 | MAPT (1.00) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL29159698 | 0.76 | MAPT (0.68) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL617934 | 0.75 | MAPT (0.55) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL11602590 | 0.74 | MAPT (0.65) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| Atrolactamide SCHEMBL78236 | 0.74 | MAPT (0.65) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| Hydrochloric Acid SCHEMBL6174190 | 0.74 | MAPT (0.95) | MAPTKMT2AKCNN4CYP2C19HIF1A | |
| SCHEMBL1706265 | 0.74 | MAPT (0.65) | MAPTKMT2AKCNN4CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | US | claimed |
| WO-2009067397-A2 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-05-28 | — | — | WO | claimed |
| CN-100571701-C | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2009-12-23 | — | — | CN | disclosed |
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | US | disclosed |
| CN-101103969-A | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-01-16 | — | — | CN | disclosed |
| CN-1753675-A | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ACAT2, ACAT1, APRT | MAPT 1442/4885KMT2A 132/4885KCNN4 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.